Biotech Acquisition Company (BIOT) Terminates Blade Deal
by Marlena Haddad on 2022-06-13 at 8:52am

Biotech Acquisition Company (NASDAQ:BIOT) announced this morning that it has mutually terminated its combination agreement with biopharmaceutical firm Blade Therapeutics.

Although the parties did not disclose the reason for the deal termination, it is likely due to unfavorable market conditions or difficulty satisfying closing conditions. But, with a deadline of January 28, 2023, the SPAC intends to continue in its efforts to identify a prospective target business for an initial business combination.

The news comes shortly after BIOT postponed its special meeting on June 3 for a second time. This meeting was first pushed back from June 1 and as with the previous postponement, Biotech noted that it had obtained sufficient votes to approve the transaction, but it needed additional time to satisfy all closing conditions. As required by Cayman Islands law, BIOT will convene the previously postponed extraordinary general meeting of shareholders tomorrow, Tuesday, June 14, 2022, at 9:00 AM Eastern Time, but intends to adjourn.

Biotech was required to maintain at least $75 million in cash available through its trust and PIPE proceeds in order for the deal to close. It initially announced a $24.3 million PIPE and signed a common stock purchase agreement on May 9 with an affiliate of Cantor Fitzgerald for it to purchase up to $75 million in the combined company’s shares post-close.

The current market pain is still creating challenging conditions for SPACs and IPOs alike, making BIOT’s deal the 24th to terminate this year. Biotech Acquisition Company initially raised $230 million in its initial public offering in January 2021, and will remain committed to finding a life-sciences partner that can deliver value for its shareholders. The SPAC is led by CEO and Chairman Dr. Michael Shleifer.

As for Blade, it will remain focused on its development plans, particularly for its differentiated lead asset, cudetaxestat, a non-competitive autotaxin inhibitor which is expected to enter a planned phase 2 clinical study in patients with idiopathic pulmonary fibrosis. Earlier this year, Blade announced that the FDA provided the feedback necessary in order for it to proceed to Phase II proof of concept and dose-ranging studies for its cudetaxestat drug candidate.

Biotech Acquisition Company initially announced its $352.8 million combination with Blade last year on November 8, 2021. San Francisco-based Blade Therapeutics is developing three drug candidates as potential therapies against varying forms of organ fibrosis with its most advanced having completed Phase I.


Recent Posts
by Kristi Marvin on 2024-06-22 at 11:30am

Terms Tracker for the Week Ending June 21, 2024 Programming Note: An abbreviated version of the Terms Tracker will be posted next week.  In light of the end of the quarter, we will be busy putting together our Half-Year report which should be posted the first week of July.  Welcome to our weekly column where...

by Nicholas Alan Clayton on 2024-06-21 at 11:46am

Future Vision II (NASDAQ:FVNNU) has filed for a $50 million IPO to hunt for a TMT target in Asia including intelligent chips, 5G and other emerging technologies there. Given the heightened competition and trade protectionism around these technologies lately, it is interesting that Future Vision II hasn’t ruled out combining with a Chinese target. In...

by Nicholas Alan Clayton on 2024-06-21 at 8:12am

At the SPAC of Dawn Every public company wants retail investor engagement, but once brought along, those investors require a bit of educating as well. Nuclear fission firm Oklo (NYSE:OKLO) is discovering that this week as it made a point to put out a press release explaining that its most recent S-1 filing was a...

by Nicholas Alan Clayton on 2024-06-20 at 3:41pm

Voyager (NASDAQ:VASHU) has filed for a SPAC IPO featuring many of the now increasingly familiar terms pushed by underwriter Cantor Fitzgerald over the past month, but does include a novel dollar figure for its raise at $261 million, before any over-allotments. Outside of this, Voyager’s trust is funded to 100.00% with $10.00 per unit to...

by Kristi Marvin on 2024-06-20 at 12:29pm

Eleven new SPACs have filed since the beginning of June, and the number is 12 if we count the May 31st filing of Graf Global Corp.  Seven of those 12 are being underwritten by Cantor, which has always been a very active SPAC underwriter. But you know who else used to be very active? Credit...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved